Technology and Cooperation

After years of technical accumulation and precipitation, the company is now engaged in the research of several projects, such as the slow and controlled release technology of solid drugs, the taste masking technology of drugs, the development of solubilization and dosage forms of insoluble drugs, and the preparation technology of topical drugs.

In the research project

Name	classification	Dosage form	Research and development phase	Project Jane interface
ZL-03	2 class	spray	preclinical	Used for the treatment of burn, scald, wound infection and bedsore wound. Using patented technology, the use of moisture and can promote wound healing polymer materials. Compared with ordinary ointment, spray film agent has the following advantages, each spray amount is accurate and controllable, the drug is evenly covered in the wound, the use of silver sulfadiazine powder, release drugs and anions quickly, the effect is good.
ZL-04	2 class	Sublingual tablet	preclinical	Treatment of heart failure and arrhythmia. It is a modified substitute for digoxin and has the characteristics of low dose, quick action and little side effect.
ZL-05	3 class	injection	preclinical	The traditional medicine supported by human assisted reproductive technology luteum is preferred. Rapid absorption after intramuscular injection, without liver metabolism, high bioavailability, definite efficacy, patented technology, no oil solvent, small side effects.
ZL-06		Slow-release suspension	preclinical	Suitable for the following infections caused by sensitive bacteria: bronchitis, pneumonia and other lower respiratory tract infections; Skin and soft tissue infections; Acute otitis media; Sinusitis, pharyngitis, tonsillitis and other upper respiratory tract infections (penicillin is the treatment of suppurative strep pharyngitis commonly used drugs, but also to prevent rheumatic fever commonly used drugs.
ZL-08	3 class	tablets	Declaration for production	Strong antihypertensive and diuretic combination of antihypertensive, good results
ZL-09	3 class	cream	preclinical	Compound miconazole nitrate hydrocortisone cream/ointment (Daktacort?) Janssen - Cilag (yeung sum pharmaceutical company UK) the second generation product of antifungal infection, successively in the countries of Europe, miconazole nitrate and hydrocortisone, can have antifungal effect, but also can make the symptoms of inflammation early subsided, and can prevent or delay in the treatment of early miconazole nitrate to the stimulation of the skin, more than miconazole nitrate cream/ointment has clinical advantages. At the same time, there are many clinical cases of combined infection of dermatitis and eczema, especially the incidence of conditional pathogenic fungal infection is very high, which makes the combined application of antibiotics and corticosteroids have certain advantages.
ZL-12	4 class	Orally disintegrating tablets	Consistency evaluation	It is also effective against insect bites and contact dermatitis. It can also be used to prevent and treat motion sickness.
ZL-13	4 class	cream	Declaration for production	Burns and scalds, diabetic feet, patented technology.
ZL-14	4 class	Oral gel	preclinical	The drug of choice for pediatric thrush and fungal infections

Drug licensee development

Name	classification	Dosage form	Research and development phase	Project Jane interface
ZC-01	2 class	Slow-release gel	preclinical	Traditional medicine supported by corpus luteum of artificial assisted reproductive technology. Rapid absorption after intramuscular injection without liver metabolism, high bioavailability, definite efficacy, patented technology, external slow-release gel, once a day.
ZC-02	3 class	injection	preclinical	The treatment of acute heart failure is characterized by low dose, quick onset and small side effects.
ZC-03	3 class	Sustained-release suppository	preclinical	Traditional medicine supported by corpus luteum of artificial assisted reproductive technology. Rapid absorption after intramuscular injection, without liver metabolism, high bioavailability, definite efficacy, patented technology, external slow-release suppository, once a day.
ZC-04	3 class	lozenges		Prophylaxis to reduce the incidence of immunocompromised patients including chemotherapy, radiotherapy, oral infection with candida oropharyngitis, as well as corticosteroid therapy for leukemia, tumors, or kidney transplant adjuvant drugs, administered three times a day, one tablet at a time, until the steroids are reduced to normal levels.
ZC-05	3 class	Vaginal tablet		Used for candidiasis vulvovaginosis.
ZC-06	3 class	Sustained-release suppository	preclinical	Europe and the United States as an important cancer radiotherapy antiemetic drugs, once a day.